The supplement enforcement pattern
Supplements operate in a high-scrutiny advertising environment on Meta. Across the accounts we monitor, we see recurring rejection patterns in supplement advertising, including cases where the visible ad appears compliant on its face. A single rejection is not, by itself, evidence of an account-level problem.
<p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">The <strong>Policy-Enforcement Gap</strong> can show up in this vertical:</p><ul class="aac-vlist"><li>Meta's policy prohibits misleading claims.</li><li>In our observations, review can catch claim-adjacent copy that would not read as misleading under other frameworks.</li><li>Repeated enforcement on an account can coincide with broader restrictions in some cases.</li></ul><p style="color:#334055;font-size:15px;line-height:1.7;margin:20px 0 12px">Similar broader-scope effects can occur across the regulated verticals we monitor. A recurring concern in this vertical is language that approaches a treatment or outcome claim. Enforcement impact can extend beyond the original ad.</p><style>.cs-cascade{background:#ffffff;color:#0d0d0d;border:1px solid #e2e7f0;border-radius:16px;padding:2rem 1.75rem;margin:1.75rem 0 0;font-family:Inter,ui-sans-serif,system-ui,sans-serif;overflow:hidden}.cs-cascade__eyebrow{font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:11px;font-weight:700;letter-spacing:0.18em;text-transform:uppercase;color:#d205bd;margin-bottom:0.5rem}.cs-cascade__title{font-family:Montserrat,ui-sans-serif,system-ui,sans-serif;font-size:1.375rem;font-weight:700;color:#0d0d0d;margin:0 0 1.5rem;line-height:1.25;letter-spacing:-0.3px}.cs-cascade__tiers{display:flex;flex-direction:column;gap:0}.cs-cascade__tier{display:grid;grid-template-columns:44px 1fr;gap:1rem;align-items:flex-start;padding:1rem 0;border-top:1px solid #e2e7f0}.cs-cascade__tier:first-child{border-top:none;padding-top:0.25rem}.cs-cascade__tier:last-child{padding-bottom:0.25rem}.cs-cascade__badge{width:40px;height:40px;border-radius:10px;display:flex;align-items:center;justify-content:center;flex-shrink:0}.cs-cascade__tier--teal .cs-cascade__badge{background:rgba(91,188,184,0.10);color:#5bbcb8}.cs-cascade__tier--amber .cs-cascade__badge{background:rgba(245,158,11,0.10);color:#f59e0b}.cs-cascade__tier--red .cs-cascade__badge{background:rgba(220,38,38,0.08);color:#dc2626}.cs-cascade__badge svg{width:20px;height:20px}.cs-cascade__body{min-width:0}.cs-cascade__pill{display:inline-block;font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:10px;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;padding:3px 8px;border-radius:999px;margin-bottom:6px;border:1px solid #e2e7f0;color:#6b7280}.cs-cascade__tier--teal .cs-cascade__pill{color:#5bbcb8;border-color:rgba(91,188,184,0.35)}.cs-cascade__tier--amber .cs-cascade__pill{color:#f59e0b;border-color:rgba(245,158,11,0.35)}.cs-cascade__tier--red .cs-cascade__pill{color:#dc2626;border-color:rgba(220,38,38,0.35)}.cs-cascade__name{font-family:Montserrat,ui-sans-serif,system-ui,sans-serif;font-size:1rem;font-weight:700;color:#0d0d0d;line-height:1.3;margin:0 0 4px}.cs-cascade__sub{font-size:0.875rem;color:#4b5563;line-height:1.5;margin:0}.cs-cascade__caption{margin-top:1.5rem;padding-top:1.25rem;border-top:1px dashed #e2e7f0;font-size:0.9375rem;color:#334055;line-height:1.6;font-style:italic}.cs-cascade__caption strong{color:#0d0d0d;font-style:normal;font-weight:700}</style><aside class="cs-cascade"><div class="cs-cascade__eyebrow">Observed scope model</div><h4 class="cs-cascade__title">From individual ad review to broader account context</h4><div class="cs-cascade__tiers"><div class="cs-cascade__tier cs-cascade__tier--teal"><div class="cs-cascade__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><circle cx="12" cy="12" r="10"/><path d="M15 9l-6 6M9 9l6 6"/></svg></div><div class="cs-cascade__body"><span class="cs-cascade__pill">Ad-level review</span><div class="cs-cascade__name">Ad-level review</div><p class="cs-cascade__sub">An individual creative or destination receives an enforcement decision.</p></div></div><div class="cs-cascade__tier cs-cascade__tier--teal"><div class="cs-cascade__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="22 17 13.5 8.5 8.5 13.5 2 7"/><polyline points="16 17 22 17 22 11"/></svg></div><div class="cs-cascade__body"><span class="cs-cascade__pill">Account-level effects</span><div class="cs-cascade__name">Account-level effects</div><p class="cs-cascade__sub">Repeated or serious enforcement can affect the account's ability to advertise.</p></div></div><div class="cs-cascade__tier cs-cascade__tier--amber"><div class="cs-cascade__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M17 21v-2a4 4 0 0 0-4-4H5a4 4 0 0 0-4 4v2"/><circle cx="9" cy="7" r="4"/><path d="M23 21v-2a4 4 0 0 0-3-3.87"/><path d="M16 3.13a4 4 0 0 1 0 7.75"/></svg></div><div class="cs-cascade__body"><span class="cs-cascade__pill">Connected-asset context</span><div class="cs-cascade__name">Connected-asset context</div><p class="cs-cascade__sub">Other connected accounts or assets may become relevant to the review.</p></div></div><div class="cs-cascade__tier cs-cascade__tier--red"><div class="cs-cascade__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><circle cx="12" cy="12" r="10"/><line x1="4.93" y1="4.93" x2="19.07" y2="19.07"/></svg></div><div class="cs-cascade__body"><span class="cs-cascade__pill">Broader business impact</span><div class="cs-cascade__name">Broader business impact</div><p class="cs-cascade__sub">Depending on the situation, enforcement can affect more than the original creative.</p></div></div></div><p class="cs-cascade__caption"><strong>Observed scope model, not a fixed Meta sequence.</strong> The affected assets, timing, and outcome vary by account, issue, and review outcome.</p></aside>
Recurring compliance considerations on supplement ads
Seven recurring compliance considerations we currently observe across supplement accounts. These are risk indicators informed by ComplyAi's analysis of enforcement outcomes and public policy requirements. They are not a substitute for Meta's published policies or a description of Meta's classifier rules.
<style>.fc-grid{display:grid;grid-template-columns:1fr;gap:1rem;margin-top:1rem}.fc-card{position:relative;background:rgba(220,38,38,0.025);border:1px solid rgba(220,38,38,0.22);border-left:4px solid #dc2626;border-radius:12px;padding:1.5rem 1.75rem}.fc-card__badge{position:absolute;top:1rem;right:1rem;display:inline-flex;align-items:center;gap:5px;font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:10px;font-weight:700;letter-spacing:0.10em;text-transform:uppercase;color:#dc2626;background:rgba(220,38,38,0.10);border:1px solid #dc2626;border-radius:4px;padding:4px 8px}.fc-card__badge svg{width:12px;height:12px}.fc-card__pill{display:inline-block;font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:12px;font-weight:700;color:#dc2626;letter-spacing:0.06em;text-transform:uppercase;margin:0 0 0.75rem;padding-right:110px}.fc-card__title{font-family:Montserrat,ui-sans-serif,system-ui,sans-serif;font-size:16px;font-weight:700;color:#0d0d0d;margin:0 0 0.75rem;line-height:1.3;padding-right:110px}.fc-card__body{font-size:0.9375rem;color:#4b5563;line-height:1.55;margin:0}@media screen and (max-width:767px){.fc-card{padding:1.25rem}.fc-card__title,.fc-card__pill{padding-right:90px}}</style><div class="fc-grid"><article class="fc-card"><span class="fc-card__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>Review concern</span><span class="fc-card__pill">Consideration 01</span><h4 class="fc-card__title">Health-claim language</h4><p class="fc-card__body">Inflammation, joint pain, energy crashes, mental fog, sleep issues framed as treatment. This is one example of what we call the Policy-Enforcement Gap. That is the difference between static policy language and how enforcement appears in practice.</p></article><article class="fc-card"><span class="fc-card__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>Review concern</span><span class="fc-card__pill">Consideration 02</span><h4 class="fc-card__title">Body-transformation imagery</h4><p class="fc-card__body">Before/after photos, weight-on-scale imagery, body-measurement visuals, fitness-transformation framing. In our observations, visual elements can create additional compliance concerns even when the copy appears compliant on its face.</p></article><article class="fc-card"><span class="fc-card__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>Review concern</span><span class="fc-card__pill">Consideration 03</span><h4 class="fc-card__title">Quantified efficacy</h4><p class="fc-card__body">Promised timelines, energy-boost percentages, named weight-loss numbers. Quantified efficacy claims can create additional compliance concerns, particularly when they promise a specific result or timeline.</p></article><article class="fc-card"><span class="fc-card__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>Review concern</span><span class="fc-card__pill">Consideration 04 · GLP-1 sub-vertical</span><h4 class="fc-card__title">Brand-name drug comparisons</h4><p class="fc-card__body">Positioning a supplement as a cheaper, natural, or equivalent alternative to a prescription drug can create additional enforcement risk. GLP-1-related supplement positioning can introduce additional compliance concerns, particularly where products are presented as alternatives to prescription treatment or as delivering comparable outcomes.</p></article><article class="fc-card"><span class="fc-card__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>Review concern</span><span class="fc-card__pill">Consideration 05</span><h4 class="fc-card__title">Celebrity or authority association</h4><p class="fc-card__body">Celebrity, clinician, or authority endorsements. Claims of professional endorsement can create additional compliance concerns, especially when credentials or affiliations cannot be verified.</p></article><article class="fc-card"><span class="fc-card__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>Review concern</span><span class="fc-card__pill">Consideration 06</span><h4 class="fc-card__title">Personal-attributes framing</h4><p class="fc-card__body">“Tired of feeling tired?” “Are you struggling with brain fog?” Product-focused framing avoids directly attributing a condition to the viewer. That distinction matters when reviewing personal-attribute language.</p></article><article class="fc-card"><span class="fc-card__badge"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>Review concern</span><span class="fc-card__pill">Consideration 07</span><h4 class="fc-card__title">Destination consistency</h4><p class="fc-card__body">An ad that appears compliant on its face can still face review when the destination contains health claims, before-and-after imagery, or quantified efficacy language. Review should cover both the ad and its destination.</p></article></div>
Practical compliance patterns for supplement brands
Five practical contrasts can help supplement brands reduce avoidable compliance risk on Meta. Each contrast separates a higher-risk framing from a generally lower-risk alternative. Neither side is automatically approved; the full ad, destination, product, and account context still matter.
<style>.pt-compare-vs{margin-top:1.5rem}.pt-compare-vs__header{display:grid;gap:1rem;grid-template-columns:1fr 120px 1fr;align-items:center;margin-bottom:2rem}@media screen and (max-width:767px){.pt-compare-vs__header{grid-template-columns:1fr 60px 1fr}}.pt-compare-vs__col-label{font-family:Montserrat,ui-sans-serif,system-ui,sans-serif;font-size:1.25rem;font-weight:700;letter-spacing:-0.3px;color:#6b7280;text-align:right}.pt-compare-vs__col-label--good{color:#5bbcb8;text-align:left}.pt-compare-vs__vs{font-family:Montserrat,ui-sans-serif,system-ui,sans-serif;font-size:1.5rem;font-weight:700;letter-spacing:0.5px;color:#d205bd;text-align:center}.pt-compare-vs__group{margin-bottom:2rem;padding-bottom:2rem;border-bottom:1px dashed #e2e7f0}.pt-compare-vs__group:last-child{margin-bottom:0;padding-bottom:0;border-bottom:none}.pt-compare-vs__row{display:grid;gap:1rem;grid-template-columns:1fr 120px 1fr;align-items:center;position:relative}@media screen and (max-width:767px){.pt-compare-vs__row{grid-template-columns:1fr;gap:0.5rem;padding:0.5rem 0}}.pt-compare-vs__pill{padding:1rem 1.25rem;border-radius:16px;font-size:0.9375rem;line-height:1.5;color:#0d0d0d;border:1px solid #e2e7f0;background:#ffffff}.pt-compare-vs__pill--bad{text-align:right;background:rgba(220,38,38,0.04);border-color:rgba(220,38,38,0.20)}.pt-compare-vs__pill--good{text-align:left;background:rgba(91,188,184,0.10);border-color:rgba(91,188,184,0.25)}@media screen and (max-width:767px){.pt-compare-vs__pill{text-align:left;border-radius:12px}}.pt-compare-vs__pill em{font-style:normal;font-weight:700;color:#0d0d0d}.pt-compare-vs__center{display:flex;flex-direction:column;align-items:center;justify-content:center;text-align:center;position:relative;min-height:88px}@media screen and (max-width:767px){.pt-compare-vs__center{flex-direction:row;justify-content:flex-start;gap:1rem;min-height:0;padding:0.5rem 0;order:0}.pt-compare-vs__pill--bad{order:1}.pt-compare-vs__pill--good{order:2}}.pt-compare-vs__icon{width:48px;height:48px;display:flex;align-items:center;justify-content:center;background:#ffffff;border:1.5px solid #d205bd;border-radius:999px;color:#d205bd;position:relative;z-index:1;flex-shrink:0}.pt-compare-vs__icon svg{width:22px;height:22px}.pt-compare-vs__label{margin-top:0.5rem;font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:11px;font-weight:700;letter-spacing:0.16em;text-transform:uppercase;color:#0d0d0d}@media screen and (max-width:767px){.pt-compare-vs__label{margin-top:0;text-align:left}}.pt-compare-vs__details{margin-top:1.25rem;padding-top:1.25rem;border-top:1px dashed #d1d5db}.pt-compare-vs__details-label{display:block;font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:10px;font-weight:700;letter-spacing:0.18em;text-transform:uppercase;color:#6b7280;margin-bottom:0.5rem}.pt-compare-vs__details p{font-size:0.9375rem;color:#4b5563;line-height:1.65;margin:0}.pt-compare-vs__details p+p{margin-top:0.75rem}.pt-compare-vs__details strong{color:#0d0d0d;font-weight:700}.pt-compare-vs__edge{display:inline-block;font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:9px;font-weight:700;letter-spacing:0.16em;text-transform:uppercase;color:#f59e0b;background:rgba(245,158,11,0.10);border:1px solid rgba(245,158,11,0.30);padding:2px 8px;border-radius:999px;margin-top:6px}</style><div class="pt-compare-vs"><div class="pt-compare-vs__header"><div class="pt-compare-vs__col-label">Higher-risk pattern</div><div class="pt-compare-vs__vs">VS</div><div class="pt-compare-vs__col-label pt-compare-vs__col-label--good">Lower-risk pattern</div></div><div class="pt-compare-vs__group"><div class="pt-compare-vs__row"><div class="pt-compare-vs__pill pt-compare-vs__pill--bad"><em>Outcome-led copy.</em> “Lose 30 lbs in 8 weeks.”</div><div class="pt-compare-vs__center"><div class="pt-compare-vs__icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M6 4 v6 a4 4 0 0 0 4 4 h4 a4 4 0 0 1 4 4 v2"/><circle cx="6" cy="4" r="2"/><circle cx="18" cy="20" r="2"/></svg></div><div class="pt-compare-vs__label">Pattern 01</div></div><div class="pt-compare-vs__pill pt-compare-vs__pill--good"><em>Process-led copy.</em> “A structured supplement routine. Monthly check-ins.”</div></div><div class="pt-compare-vs__details"><span class="pt-compare-vs__details-label">Why this distinction matters</span><p>Process-led language can be less explicit than outcome-led language because it describes the service or routine rather than promising a specific customer result.</p></div></div><div class="pt-compare-vs__group"><div class="pt-compare-vs__row"><div class="pt-compare-vs__pill pt-compare-vs__pill--bad"><em>Therapeutic-claim language.</em> “Treats afternoon fatigue.”</div><div class="pt-compare-vs__center"><div class="pt-compare-vs__icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M21 15 a2 2 0 0 1 -2 2 H7 l-4 4 V5 a2 2 0 0 1 2-2 h14 a2 2 0 0 1 2 2 z"/></svg></div><div class="pt-compare-vs__label">Pattern 02</div></div><div class="pt-compare-vs__pill pt-compare-vs__pill--good"><em>Customer-state language.</em> “Supports your morning routine.”</div></div><div class="pt-compare-vs__details"><span class="pt-compare-vs__details-label">Why this distinction matters</span><p>The distinction is between describing a wellness routine and making a claim about treating a condition.</p></div></div><div class="pt-compare-vs__group"><div class="pt-compare-vs__row"><div class="pt-compare-vs__pill pt-compare-vs__pill--bad"><em>Missing applicable structure/function disclosure.</em> No FDA disclaimer where a qualifying structure/function claim would require one.</div><div class="pt-compare-vs__center"><div class="pt-compare-vs__icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M12 22 s8-4 8-10 V5 l-8-3 -8 3 v7 c0 6 8 10 8 10 z"/><path d="m9 12 2 2 4-4"/></svg></div><div class="pt-compare-vs__label">Pattern 03</div></div><div class="pt-compare-vs__pill pt-compare-vs__pill--good"><em>Structure/function disclosure where required.</em> Include the FDA disclaimer when required for the relevant structure/function claim.</div></div><div class="pt-compare-vs__details"><span class="pt-compare-vs__details-label">Why it matters</span><p>Under U.S. FDA rules, structure/function claims and disease claims are treated differently. Where a structure/function claim requires a disclaimer under applicable U.S. rules, brands should follow those requirements. A disclaimer does not convert a prohibited disease claim into a compliant one. FDA and Meta review are separate layers.</p></div></div><div class="pt-compare-vs__group"><div class="pt-compare-vs__row"><div class="pt-compare-vs__pill pt-compare-vs__pill--bad"><em>Generic credential.</em> “Doctor-recommended.”</div><div class="pt-compare-vs__center"><div class="pt-compare-vs__icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M12 15 a4 4 0 1 0 0-8 a4 4 0 0 0 0 8 z"/><path d="m9 14 -2 7 5-3 5 3 -2-7"/></svg></div><div class="pt-compare-vs__label">Pattern 04</div></div><div class="pt-compare-vs__pill pt-compare-vs__pill--good"><em>Verifiable professional credentials.</em> Named credentials that can be independently verified.</div></div><div class="pt-compare-vs__details"><span class="pt-compare-vs__details-label">Why it matters</span><p>Professional credentials should be accurate, current, and independently supportable. A credential does not make an otherwise unsupported health claim compliant. Relevant for telehealth-adjacent brands and any brand citing clinical authority.</p></div></div><div class="pt-compare-vs__group"><div class="pt-compare-vs__row"><div class="pt-compare-vs__pill pt-compare-vs__pill--bad"><em>Category-specific verification not completed.</em> Healthcare or pharmacy-adjacent products may face additional platform or merchant-verification requirements.</div><div class="pt-compare-vs__center"><div class="pt-compare-vs__icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M3 21 V8 l9-5 9 5 v13"/><path d="M9 21 V12 h6 v9"/><path d="M3 21 h18"/></svg></div><div class="pt-compare-vs__label">Pattern 05</div><span class="pt-compare-vs__edge">Edge case</span></div><div class="pt-compare-vs__pill pt-compare-vs__pill--good"><em>Verify the applicable certification for the category.</em> Treat merchant-verification requirements as category-specific, not universal to supplements.</div></div><div class="pt-compare-vs__details"><span class="pt-compare-vs__details-label">When this applies</span><p>Healthcare or pharmacy-adjacent products may face additional platform or merchant-verification requirements. The applicable certification depends on the product, business model, market, and platform. Treat LegitScript's Healthcare Merchant Certification as a category-specific check, not a supplement default. Do not assume that every supplement business requires this certification. Verify the applicable requirements for the specific product, business model, market, and platform.</p></div></div></div>
What to review when supplement ads face enforcement
Recovery is the highest-stakes surface on this page. Time off-air compounds quickly, and the appropriate response depends on the specific decision, the affected asset, and the account's current status. ComplyAi helps identify the underlying issue behind an enforcement event so teams can choose whether to revise, replace, or appeal the affected asset.
<style>.st-list{display:flex;flex-direction:column;gap:0;margin:0.75rem 0 0;background:#ffffff;border:1px solid #e2e7f0;border-radius:16px;padding:1.25rem 2rem}@media screen and (max-width:767px){.st-list{padding:1rem 1.25rem}}.st-stage{display:flex;flex-direction:column;padding:1.75rem 0;border-bottom:1px solid #e2e7f0}.st-stage:last-child{border-bottom:none;padding-bottom:0.25rem}.st-stage:first-child{padding-top:0}.st-stage__head{display:flex;align-items:flex-start;gap:1rem;margin-bottom:1rem;flex-wrap:wrap}.st-stage__num{font-family:Montserrat,ui-sans-serif,system-ui,sans-serif;font-size:3rem;font-weight:700;line-height:0.9;letter-spacing:-1px;flex-shrink:0;margin-top:-0.15em}.st-stage--01 .st-stage__num{color:#eab308}.st-stage--02 .st-stage__num{color:#f59e0b}.st-stage--03 .st-stage__num{color:#f97316}.st-stage--04 .st-stage__num{color:#dc2626}.st-stage__heads{display:flex;flex-direction:column;gap:0.35rem;flex:1;min-width:0;padding-top:0.1rem}.st-stage__name{font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:11px;font-weight:700;letter-spacing:0.16em;text-transform:uppercase;line-height:1;color:#6b7280;margin:0}.st-stage--01 .st-stage__name{color:#eab308}.st-stage--02 .st-stage__name{color:#f59e0b}.st-stage--03 .st-stage__name{color:#f97316}.st-stage--04 .st-stage__name{color:#dc2626}.st-stage__title{font-family:Montserrat,ui-sans-serif,system-ui,sans-serif;font-size:16px;font-weight:700;color:#0d0d0d;margin:0;line-height:1.2;letter-spacing:-0.4px}@media screen and (max-width:767px){.st-stage__title{font-size:16px}.st-stage__num{font-size:2.5rem}}.st-stage__body{font-size:1rem;color:#4b5563;line-height:1.65;margin:0 0 1rem;max-width:78ch}.st-stage__anchor{padding-top:1rem;border-top:1px dashed #e2e7f0;max-width:78ch}.st-stage__anchor-label{display:block;font-family:ui-monospace,"SF Mono",Menlo,Consolas,monospace;font-size:10px;font-weight:700;letter-spacing:0.10em;text-transform:uppercase;margin-bottom:4px}.st-stage--01 .st-stage__anchor-label{color:#eab308}.st-stage--02 .st-stage__anchor-label{color:#f59e0b}.st-stage--03 .st-stage__anchor-label{color:#f97316}.st-stage--04 .st-stage__anchor-label{color:#dc2626}.st-stage__anchor-text{font-size:0.9375rem;color:#0d0d0d;line-height:1.6;margin:0}</style><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">Enforcement can expand from a single ad to broader scopes. In our observations, the trajectory matters more than any single rejection. The four stages below describe how enforcement scope can change. Each one notes what shifts at that stage.</p><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 20px">These stages are a practical mental model, not a fixed Meta sequence. Outcomes vary by account, enforcement scope, and the information available for review.</p><div class="st-list"><div class="st-stage st-stage--01"><div class="st-stage__head"><div class="st-stage__num">01</div><div class="st-stage__heads"><span class="st-stage__name">Ad-level enforcement</span><h4 class="st-stage__title">A single ad is under enforcement</h4></div></div><p class="st-stage__body">The event is limited to ad-level enforcement. The creative, destination, and available enforcement notice are the most relevant starting points for review.</p><div class="st-stage__anchor"><span class="st-stage__anchor-label">What changes</span><p class="st-stage__anchor-text">Scope is limited to the ad-level event. Review the creative, destination, and available enforcement notice.</p></div></div><div class="st-stage st-stage--02"><div class="st-stage__head"><div class="st-stage__num">02</div><div class="st-stage__heads"><span class="st-stage__name">Account-level impact</span><h4 class="st-stage__title">The account is affected beyond a single creative</h4></div></div><p class="st-stage__body">Repeated enforcement may affect the account beyond a single creative. Reviewing recent enforcement history can be more useful than considering one rejection in isolation.</p><div class="st-stage__anchor"><span class="st-stage__anchor-label">What changes</span><p class="st-stage__anchor-text">Review expands from the individual creative to the account's recent enforcement history.</p></div></div><div class="st-stage st-stage--03"><div class="st-stage__head"><div class="st-stage__num">03</div><div class="st-stage__heads"><span class="st-stage__name">Broader connected scope</span><h4 class="st-stage__title">The scope has expanded beyond an individual ad account</h4></div></div><p class="st-stage__body">Connected accounts and business assets may become relevant depending on the scope of the enforcement event.</p><div class="st-stage__anchor"><span class="st-stage__anchor-label">What changes</span><p class="st-stage__anchor-text">Scope broadens from one ad account to connected accounts and assets under the same Business Manager.</p></div></div><div class="st-stage st-stage--04"><div class="st-stage__head"><div class="st-stage__num">04</div><div class="st-stage__heads"><span class="st-stage__name">Multi-surface scope</span><h4 class="st-stage__title">Enforcement can involve multiple connected surfaces</h4></div></div><p class="st-stage__body">Depending on the situation, enforcement may affect more than the original ad account. The relevant scope can include connected accounts, Pages, domains, or other business assets.</p><div class="st-stage__anchor"><span class="st-stage__anchor-label">What changes</span><p class="st-stage__anchor-text">Scope now spans multiple connected surfaces, not a single ad or account.</p></div></div></div><p style="color:#334055;font-size:15px;line-height:1.7;margin:20px 0 0">Broader guidance on account-level enforcement lives at <a href="/blog/meta-ad-account-reinstatement" class="aac-vlink">Meta Ad Account Reinstatement</a>, the Pillar 2 hub for accounts already restricted, suspended, or affected by broader enforcement.</p>
What cross-account context adds
A brand watching its own Business Manager sees its own rejection history. Cross-account context can help place individual events alongside recurring issues observed across similar advertisers.
<p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">A brand watching its own Business Manager sees its own rejection history. Cross-account context can help place individual events alongside recurring issues observed across similar advertisers.</p><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">For supplements, the Graph surfaces:</p><ul class="aac-vlist"><li><strong>Recurring copy patterns associated with enforcement outcomes across similar accounts.</strong></li><li><strong>Recurring visual and landing-page concerns across the vertical.</strong></li><li><strong>Broader changes in enforcement behavior that may not be visible from one account alone.</strong></li><li><strong>Cross-account context for distinguishing isolated events from broader patterns.</strong></li><li><strong>What we call the Enforcement Signal Layer.</strong> A ComplyAi interpretation layer that adds context to enforcement information available through connected platform data.</li><li><strong>Connected-asset context</strong> that helps advertisers understand whether an enforcement event may have broader business implications.</li></ul>